Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Young-Suk | - |
dc.contributor.author | Gwak, Geum-Youn | - |
dc.contributor.author | Choi, Jonggi | - |
dc.contributor.author | Lee, Yung Sang | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.contributor.author | Yoo, Byung Chul | - |
dc.contributor.author | Kwon, So Young | - |
dc.contributor.author | Lee, Han Chu | - |
dc.date.available | 2020-11-02T06:34:19Z | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 0168-8278 | - |
dc.identifier.issn | 1600-0641 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/1837 | - |
dc.description.abstract | Background & Aims Tenofovir disoproxil fumarate (TDF) monotherapy has displayed non-inferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with hepatitis B virus (HBV) resistant to ETV and/or adefovir (ADV). Nonetheless, the virologic response rate was suboptimal in patients receiving up to 144 weeks of TDF monotherapy. We aimed to assess the efficacy and safety of TDF monotherapy given for up to 240 weeks. Methods One trial enrolled patients with ETV resistance without ADV resistance (n = 90), and another trial included patients with ADV resistance (n = 102). Most patients (91.2%) also had lamivudine resistance. Patients were randomized 1:1 to receive TDF monotherapy or TDF + ETV combination therapy for 48 weeks, and then TDF monotherapy until week 240. We compared efficacy between the studies and safety in the pooled population at 240 weeks. Results At week 240, the proportion of patients with serum HBV DNA <15 IU/ml was not significantly different between the ETV and ADV resistance groups in the full analysis set (84.4% vs. 73.5%; p = 0.07), which was significantly different by on-treatment analysis (92.7% vs. 79.8%; p = 0.02). Virologic blips associated with poor medication adherence occurred in 7 patients throughout the 240 weeks. None developed additional HBV resistance mutations. Among the 170 HBV e antigen (HBeAg)-positive patients at baseline, 12 (7.1%) achieved HBeAg seroconversion at week 240. None achieved HBV surface antigen seroclearance. Significant decreases from baseline were observed at week 240 in the estimated glomerular filtration rate (−3.21 ml/min/1.73 m2 by the CKD-EPI equation, p <0.001) and bone mineral density (g/cm2) at the femur (−2.48%, p <0.001). Conclusions Up to 240 weeks of TDF monotherapy provided an increasing virologic response rate in heavily pretreated patients with HBV resistant to ETV and/or ADV. However, it was associated with poor serological responses and decreasing renal function and bone mineral density. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial | - |
dc.type | Article | - |
dc.publisher.location | 네델란드 | - |
dc.identifier.doi | 10.1016/j.jhep.2019.02.021 | - |
dc.identifier.scopusid | 2-s2.0-85064084109 | - |
dc.identifier.wosid | 000471646900007 | - |
dc.identifier.bibliographicCitation | Journal of Hepatology, v.71, no.1, pp 35 - 44 | - |
dc.citation.title | Journal of Hepatology | - |
dc.citation.volume | 71 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 35 | - |
dc.citation.endPage | 44 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | VIRUS INFECTION | - |
dc.subject.keywordPlus | ANALOG THERAPY | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | EMTRICITABINE | - |
dc.subject.keywordPlus | ALAFENAMIDE | - |
dc.subject.keywordPlus | DIPIVOXIL | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | FAILURE | - |
dc.subject.keywordAuthor | Adefovir dipivoxil | - |
dc.subject.keywordAuthor | Entecavir | - |
dc.subject.keywordAuthor | Hepatitis B virus | - |
dc.subject.keywordAuthor | Lamivudine | - |
dc.subject.keywordAuthor | Resistance | - |
dc.subject.keywordAuthor | HBV | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.